A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

The F.D.A. lists semaglutide, the compound in Ozempic and the weight loss drug Wegovy, as currently in shortage. “Many people, unfortunately, cannot get it,” Dr. Hoenig said. “But if they ...

Semaglutide is the active ingredient in diabetes drug Ozempic and obesity medication Wegovy (since Wegovy was approved in 2021, Ozempic has become a common off-label treatment for obesity).

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

Ozempic and other semaglutide injections such as Wegovy have been in short supply for years due to their rapid popularity. The FDA now lists Ozempic as “available,” but there is still high demand.

Due to occasional supply chain issues, Ozempic may be difficult to get. In these cases, your healthcare professional may recommend an alternative, such as Wegovy, Zepbound, or Mounjaro.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is ...

Ozempic alternatives offer a variety of options for those who want to switch due to side effects, availability, or cost. Below is a breakdown of readily available alternatives, all vetted by our ...

THEY'RE ADVERTISED AS OZEMPIC OR WEGOVY. 12;40;15;00 THE GENERIC NAME IS SEMAGLUTIDE, THESE ARE IN A CLASS OF MEDICATIONS CALLED GLP1. DR. COHEN SAYS THIS IS A NATURALLY OCCURING HORMONE THAT CUES ...